Advertisement
Forex Nyheter
TSX Ends Lower For 4th Straight Session
The Canadian market ended weak on Wednesday, weighed down by losses in technology, real estate, consumer staples and consumer discretionary sectors.
RTTNews |
782 dagar sedan
Dollar Loses Ground Against Major Rivals Despite Powell's Hawkish Comments
The U.S. dollar shed ground against its major counterparts on Wednesday despite Federal Reserve Chair Jerome Powell, who testified before the House Financial Services Committee today, reiterating that the central bank will likely continue raising rates to contain inflation.
RTTNews
|
782 dagar sedan
Canadian Market Roughly Flat In Cautious Trade After Paring Early Losses
The Canadian market is down marginally Wednesday afternoon with stocks turning in a mixed performance amid lingering concerns about interest rates and slowing growth.
RTTNews
|
782 dagar sedan
Swiss Market Fails To Hold Early Gains, Ends Modestly Lower
After a weak start and a subsequent recovery that resulted in a positive spell till about an hour past noon on Wednesday, the Switzerland market fell into negative territory and eventually ended the day's session modestly lower.
RTTNews
|
782 dagar sedan
European Stocks Close Lower After Hawkish Comments From Powell
European stocks closed weak on Wednesday, extending recent losses, as Federal Reserve Chair Jerome Powell reaffirmed the central bank's commitment to bringing inflation down to its target rate of 2%.
RTTNews
|
782 dagar sedan
Canadian Dollar Advances After Upbeat Retail Sales Data
The Canadian dollar climbed against its major counterparts during the New York session on Wednesday, as the nation's retail sales exceeded expectations in April.
RTTNews
|
782 dagar sedan
Aldeyra Therapeutics Gets CRL From FDA For NDA Of ADX-2191 To Treat Primary Vitreoretinal Lymphoma
Biotechnology company Aldeyra Therapeutics, Inc. (ALDX) announced Wednesday the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL).
RTTNews
|
782 dagar sedan
more news
Powell Expects Further Rate Hikes As Inflation Remains Stubbornly Elevated
Following last week's widely expected pause, the Federal Reserve is likely to resume raising interest rates later this year, Fed Chair Jerome Powell said during testimony before the House Financial Services Committee on Wednesday.
RTTNews
|
782 dagar sedan
DiaMedica Therapeutics Says FDA Lifts Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
Biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) announced Wednesday that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS).
RTTNews
|
782 dagar sedan
Bay Street Likely To See Subdued Start
Canadian shares are likely to open on a somewhat subdued note on Wednesday, amid a lack of positive triggers.
RTTNews
|
782 dagar sedan
Winnebago Industries Q3 Net Profit Halves, But Adj. EPS Tops Estimates
Recreation vehicles maker Winnebago Industries, Inc. (WGO) reported on Wednesday that third-quarter net income plunged to $59.1 million or $1.71 per share from $117.2 million or $3.57 per share in the prior-year quarter.
RTTNews
|
782 dagar sedan
Pound Drops On Rate Hike Worries After Strong Inflation Data
The pound fell against its major rivals in the European session on Wednesday, as the nation's inflation came in well above consensus expectations in May, raising concerns about a bigger rate hike from the Bank of England at the monetary policy decision on Thursday.
RTTNews
|
782 dagar sedan
Bluebird Bio Says FDA Accepts BLA For Lovotibeglogene Autotemcel For Priority Review
bluebird bio, Inc. (BLUE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) for priority review. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2023.
RTTNews
|
782 dagar sedan
Stay up to date!
Add Nyheter to your browser
Add To Chrome
